세계의 공간 유전체학 및 전사체학 시장 규모, 점유율, 동향 분석 리포트 : 기술별, 제품별, 최종 용도별, 지역별, 부문 동향(2023-2030년)

Spatial Genomics & Transcriptomics Market Growth & Trends

The global spatial genomics & transcriptomics market size is expected to reach USD 574.3 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 12.2% from 2023 to 2030. The market is poised for significant growth over the forecast period owing to the increasing potential of spatial genomic analysis as a cancer detection method and the advent of the latest generation of sequencing technology.

The shift toward personalized medicine, which aims to provide tailored healthcare based on individual characteristics, is driving the demand for spatial genomics and transcriptomics. These technologies offer a comprehensive view of the genetic and molecular landscape within patient tissues, enabling precise diagnosis, prognosis, and treatment selection. Spatial genomics and transcriptomics facilitate the identification of specific gene expression patterns associated with disease subtypes, allowing clinicians to make informed decisions about personalized treatment strategies.

The market for spatial genomics & transcriptomics has witnessed significant technological advancements in recent years. Companies have been investing in research and development to improve the accuracy, scalability, and affordability of spatial genomics and transcriptomics platforms. Additionally, the market has seen the introduction of user-friendly and integrated solutions that simplify data analysis and interpretation, making these technologies more accessible to a broader user base.

For instance, in April 2023, Vizgen launched the world's first single-cell spatial genomics platform based on MERFISH technology. The device offers high resolution and maximum efficiency to profile the transcriptome. These advancements have expanded the market potential and attracted investments from both academic and industry sectors.

Spatial Genomics & Transcriptomics Market Report Highlights

• The spatial transcriptomics technology segment accounted for the largest revenue share in 2022, owing to their high adoption as compared to spatial genomic methods, for the transcriptomic study of single cells
• The consumables segment is expected to grow at the fastest CAGR during the forecast period, as this segment covers products that are required to run the instruments across various stages of genome mapping from sample preparation to result derivation
• The translational research segment accounted for the highest revenue share in 2022, because the use of spatial omics technologies in translational research may potentially benefit research by providing a thorough analysis of physiology & state of a disease
• Asia Pacific is anticipated to be growing at the fastest CAGR over the forecast period due to the presence of untapped opportunities in the emerging economies of China and India
• A few major market players include Natera Inc.; 10x Genomics; Dovetail Genomics; Illumina, Inc.; and S2 Genomics, Inc.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Information Analysis
  • 1.2.2. Market Formulation & Data Visualization
  • 1.2.3. Data Validation & Publishing
• 1.3. Research Assumptions
• 1.4. Information Procurement
  • 1.4.1. Primary Research
• 1.5. Information or Data Analysis
• 1.6. Market Formulation & Validation
• 1.7. Market Model
• 1.8. Global Market: CAGR Calculation
• 1.9. Objective
  • 1.9.1. Objective 1
  • 1.9.2. Objective2

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Emerging potential of spatial genomic analysis as a cancer diagnostic tool
    • 3.2.1.2. Advent of the fourth generation of sequencing (in situ sequencing)
    • 3.2.1.3. Emerging players can boost the market competitiveness
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Slow implementation of technology
    • 3.2.2.2. Well-established workflows for conventional genomics & transcriptomics analysis
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

• 4.1. Spatial Genomics & Transcriptomics Market: Technology Movement Analysis
• 4.2. Spatial Transcriptomics
  • 4.2.1. Global Spatial Transcriptomics Market, 2018 - 2030 (USD Million)
  • 4.2.2. Sequencing-based methods
    • 4.2.2.1. Global sequencing-based methods Market, 2018 - 2030 (USD Million)
    • 4.2.2.2. Laser Capture Microdissection (LCM)
    • 4.2.2.2.1. Global LCM market for spatial transcriptomics, 2018 - 2030 (USD Million)
    • 4.2.2.2.2. LCM using FFPE Tissue Samples
    • 4.2.2.2.2.1. Global FFPE tissue samples-based LCM market for spatial transcriptomics, 2018 - 2030 (USD Million)
    • 4.2.2.2.3. LCM using other Tissue Samples
    • 4.2.2.2.3.1. Global other tissue samples-based LCM market for spatial transcriptomics, 2018 - 2030 (USD Million)
    • 4.2.2.3. Transcriptome In-vivo Analysis (TIVA)
    • 4.2.2.3.1. Global TIVA market for spatial transcriptomics, 2018 - 2030 (USD Million)
    • 4.2.2.4. In situ sequencing
    • 4.2.2.4.1. Global In situ sequencing market for spatial transcriptomics, 2018 - 2030 (USD Million)
    • 4.2.2.5. Microtomy sequencing
    • 4.2.2.5.1. Global microtomy sequencing market for spatial transcriptomics, 2018 - 2030 (USD Million)
  • 4.2.3. IHC
    • 4.2.3.1. Global IHC Market, 2018 - 2030 (USD Million)
  • 4.2.4. Microscopy-based RNA imaging techniques
    • 4.2.4.1. Global microscopy-based RNA imaging techniques Market, 2018 - 2030 (USD Million)
    • 4.2.4.2. Single Molecule RNA fluorescence In-Situ Hybridization (smFISH)
    • 4.2.4.2.1. Global Single Molecule RNA fluorescence In-Situ Hybridization (smFISH) market for spatial transcriptomics, 2018 - 2030 (USD Million)
    • 4.2.4.3. Padlock Probes/Rolling Circle Amplification
    • 4.2.4.3.1. Global Padlock Probes/Rolling Circle Amplification market for spatial transcriptomics, 2018 - 2030 (USD Million)
    • 4.2.4.4. Branched DNA Probes
    • 4.2.4.4.1. Global Branched DNA probes market for spatial transcriptomics, 2018 - 2030 (USD Million)
• 4.3. Spatial Genomics
  • 4.3.1. Global spatial genomics Market, 2018 - 2030 (USD Million)
  • 4.3.2. FISH
    • 4.3.2.1. Global FISH Market for spatial genomics, 2018 - 2030 (USD Million)
  • 4.3.3. Microscopy-based Live DNA Imaging
    • 4.3.3.1. Global Microscopy-based Live DNA Imaging Market for spatial genomics, 2018 - 2030 (USD Million)
  • 4.3.4. Genome Perturbation tools
    • 4.3.4.1. Global genome perturbation tools Market for spatial genomics, 2018 - 2030 (USD Million)
  • 4.3.5. Massively-Parallel Sequencing
    • 4.3.5.1. Global massively-parallel sequencing Market for spatial genomics, 2018 - 2030 (USD Million)
  • 4.3.6. Biochemical Techniques
    • 4.3.6.1. Global biochemical techniques Market for spatial genomics, 2018 - 2030 (USD Million)
  • 4.3.7. Others
    • 4.3.7.1. Global others Market for spatial genomics, 2018 - 2030 (USD Million)

Chapter 5. Product Business Analysis

• 5.1. Spatial Genomics & Transcriptomics Market: Product Movement Analysis
• 5.2. Instruments
  • 5.2.1. Global Instruments Market for Spatial Genomics & Transcriptomics, 2018 - 2030 (USD Million)
  • 5.2.2. By Mode
    • 5.2.2.1. Automated
    • 5.2.2.1.1. Global automated Market, 2018 - 2030 (USD Million)
    • 5.2.2.2. Semi-Automated
    • 5.2.2.2.1. Global semi-automated Market, 2018 - 2030 (USD Million)
    • 5.2.2.3. Manual
    • 5.2.2.3.1. Global manual Market, 2018 - 2030 (USD Million)
  • 5.2.3. By Type
    • 5.2.3.1. Sequencing Platforms
    • 5.2.3.1.1. Global sequencing platforms Market, 2018 - 2030 (USD Million)
    • 5.2.3.2. IHC
    • 5.2.3.2.1. Global IHC Market, 2018 - 2030 (USD Million)
    • 5.2.3.3. Microscopy
    • 5.2.3.3.1. Global microscopy Market, 2018 - 2030 (USD Million)
    • 5.2.3.4. Flow Cytometry
    • 5.2.3.4.1. Global flow cytometry Market, 2018 - 2030 (USD Million)
    • 5.2.3.5. Mass Spectrometry
    • 5.2.3.5.1. Global mass spectrometry Market, 2018 - 2030 (USD Million)
    • 5.2.3.6. Others
    • 5.2.3.6.1. Global others Market, 2018 - 2030 (USD Million)
• 5.3. Consumables
  • 5.3.1. Global consumables Market for Spatial Genomics & Transcriptomics, 2018 - 2030 (USD Million)
• 5.4. Software
  • 5.4.1. Global software Market for Spatial Genomics & Transcriptomics, 2018 - 2030 (USD Million)
  • 5.4.2. Bioinformatics Tools
    • 5.4.2.1. Global bioinformatics tools Market for Spatial Genomics & Transcriptomics, 2018 - 2030 (USD Million)
  • 5.4.3. Imaging Tools
    • 5.4.3.1. Global imaging tools Market for Spatial Genomics & Transcriptomics, 2018 - 2030 (USD Million)
  • 5.4.4. Storage and Management Databases
    • 5.4.4.1. Global storage and management databases Market for Spatial Genomics & Transcriptomics, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

• 6.1. Spatial Genomics & Transcriptomics Market: End-use Movement Analysis
• 6.2. Translational Research
  • 6.2.1. Global spatial genomics & transcriptomics-based translational research market, 2018 - 2030 (USD Million)
• 6.3. Academic Customers
  • 6.3.1. Global spatial genomics & transcriptomics-based academic customers market, 2018 - 2030 (USD Million)
• 6.4. Diagnostic Customers
  • 6.4.1. Global spatial genomics & transcriptomics-based diagnostic customers market, 2018 - 2030 (USD Million)
• 6.5. Pharmaceutical Manufacturer
  • 6.5.1. Global spatial genomics & transcriptomics-based pharmaceutical manufacturer market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Spatial Genomics & Transcriptomics Market Share By Region, 2022 & 2030
• 7.2. North America
  • 7.2.1. SWOT Analysis
  • 7.2.2. North America Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.2.3. U.S.
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Target Disease Prevalence
    • 7.2.3.3. Competitive Scenario
    • 7.2.3.4. Regulatory Framework
    • 7.2.3.5. U.S. Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.2.4. Canada
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Target Disease Prevalence
    • 7.2.4.3. Competitive Scenario
    • 7.2.4.4. Regulatory Framework
    • 7.2.4.5. Canada Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. SWOT Analysis
  • 7.3.2. Europe Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.3.3. UK
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Regulatory Framework
    • 7.3.3.5. UK Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.3.4. Germany
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target Disease Prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. Regulatory Framework
    • 7.3.4.5. Germany Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.3.5. France
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Target Disease Prevalence
    • 7.3.5.3. Competitive Scenario
    • 7.3.5.4. Regulatory Framework
    • 7.3.5.5. France Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.3.6. Italy
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Target Disease Prevalence
    • 7.3.6.3. Competitive Scenario
    • 7.3.6.4. Regulatory Framework
    • 7.3.6.5. Italy Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.3.7. Spain
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Target Disease Prevalence
    • 7.3.7.3. Competitive Scenario
    • 7.3.7.4. Regulatory Framework
    • 7.3.7.5. Spain Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.3.8. Denmark
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Target Disease Prevalence
    • 7.3.8.3. Competitive Scenario
    • 7.3.8.4. Regulatory Framework
    • 7.3.8.5. Denmark Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.3.9. Sweden
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Target Disease Prevalence
    • 7.3.9.3. Competitive Scenario
    • 7.3.9.4. Regulatory Framework
    • 7.3.9.5. Sweden Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.3.10. Norway
    • 7.3.10.1. Key Country Dynamics
    • 7.3.10.2. Target Disease Prevalence
    • 7.3.10.3. Competitive Scenario
    • 7.3.10.4. Regulatory Framework
    • 7.3.10.5. Norway Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. SWOT Analysis
  • 7.4.2. Asia Pacific Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Regulatory Framework
    • 7.4.3.5. Japan Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.4.4. China
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. Regulatory Framework
    • 7.4.4.5. China Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.4.5. India
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Regulatory Framework
    • 7.4.5.5. India Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Regulatory Framework
    • 7.4.6.5. Australia Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. Regulatory Framework
    • 7.4.7.5. Thailand Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.4.8. South Korea
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Target Disease Prevalence
    • 7.4.8.3. Competitive Scenario
    • 7.4.8.4. Regulatory Framework
    • 7.4.8.5. South Korea Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. SWOT Analysis
  • 7.5.2. Latin America Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.5.3. Brazil
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Regulatory Framework
    • 7.5.3.5. Brazil Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. Regulatory Framework
    • 7.5.4.5. Mexico Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.5.5. Argentina
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Competitive Scenario
    • 7.5.5.4. Regulatory Framework
    • 7.5.5.5. Argentina Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
• 7.6. MEA
  • 7.6.1. SWOT Analysis
  • 7.6.2. MEA Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.6.3. South Africa
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Regulatory Framework
    • 7.6.3.5. South Africa Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.6.4. Saudi Arabia
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. Regulatory Framework
    • 7.6.4.5. Saudi Arabia Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.6.5. UAE
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Regulatory Framework
    • 7.6.5.5. UAE Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)
  • 7.6.6. Kuwait
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Competitive Scenario
    • 7.6.6.4. Regulatory Framework
    • 7.6.6.5. Kuwait Spatial Genomics & Transcriptomics Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share Analysis, 2022
• 8.4. Company Profiles/Listing
  • 8.4.1. Natera, Inc.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. 10x Genomics
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Dovetail Genomics
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Illumina, Inc.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. S2 Genomics, Inc.
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Nanostring Technologies, Inc.
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Seven Bridges Genomics
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Horizon Discovery Group plc
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Bio-Techne
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives